Anaveon

Anaveon is a Swiss, private biotech founded in 2017, operating in the late preclinical stage with a focus on precision biologics for immune-mediated diseases. Its lead asset, ANV200, is an engineered antibody designed for deep depletion of PD-1-expressing pathogenic T cells, with clinical testing planned in the near future. The company is led by a seasoned executive team with deep immunology and biopharma business development expertise, positioning it to advance its pipeline and seek strategic partnerships for growth.

Precision-engineered antibody platform targeting upstream regulatory nodes of the immune system (e.g., PD-1) for selective depletion or reprogramming of pathogenic immune cells.

The autoimmune space is crowded with large pharma and biotech companies developing cytokine inhibitors, JAK inhibitors, and other T-cell modulators. Anaveon's direct competition includes other companies developing T-cell depleting or modulating therapies, but its specific focus on PD-1 for depletion in autoimmunity is a distinct and unproven approach.